Search
Displaying 911–920 of 1010 results
-
ARVO 2016: Emerging Drug Targets Toxic Build-Up in Stargardt Disease
Research NewsIn August 2015, the biotech company Alkeus launched a multi-center TEASE Phase II clinical trial for the drug ALK-001.
-
ARVO 2016: What Does It Take to Develop a Stem-Cell Therapy for the Retina?
Research NewsThere are innumerable considerations for researchers developing therapies.
-
ARVO 2016: ProgSTAR, FFB-CRI's Stargardt Disease Patient Study, Highlighted
Research NewsWhen the study and the reports are completed, the ProgSTAR database will be made available to researchers and companies developing therapies.
-
ARVO 2016: Choroideremia Gene Therapy in Clinical Trial Continues to Perform Well
Research NewsFive of six patients in NightStaRx’s choroideremia gene-therapy trial continue to benefit from the treatment.
-
Foundation Fighting Blindness Announces Leadership Succession Plan After 45 Year Legacy
Foundation NewsDavid Brint has been elected Chairman, effective July 1, 2016. Brint succeeds co-founder and current Chairman, Gordon Gund, who will remain a member of the Board of Directors and will continue to be actively involved in the Foundation’s Research Oversight Committee
-
Two New Videos Highlight the Foundation's Vital Role in Retinal Research
Research NewsDr. Shannon Boye and her Foundation-funded research is the subject of not just one but two new Foundation videos.
-
Retinal Researchers May Be Looking for You
Research NewsIf you have a heritable retinal disease, consider registering with My Retina Tracker, the Foundation’s free, secure and confidential registry for people with inherited retinal diseases.
-
Past Sun Exposure Increases AMD Risk
Research NewsResearchers from the University of Cologne in Germany and Radboud University in the Netherlands found that increased sunlight exposure during working life significantly increases risk of AMD later in life.
-
A Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
Research NewsA Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
-
The Challenge Continues: FFB Chairman Gordon Gund is Interviewed on CNBC
In the PressIn a recent interview with CNBC’ s Brian Sullivan, during a tech-investor conference in Nantucket, Gordon explained why this is such a crucial time in retinal-research history.
